The authors have declared no conflicts of interest. This retrospective, multicentre study included 96 patients with SSc and refractory DUs: 32 treated with selexipag (median dose of 1,600 mg/day; ...

We wanted to review whether a group of drugs called prostacyclin analogues help people with pulmonary hypertension. Cochrane researchers collected and analysed all relevant studies to answer this ...

Please provide your email address to receive an email when new articles are posted on . Researchers used data from the GRIPHON study and open-label extension study. The median selexipag dose was 1,000 ...

The results revealed a 45% lower risk of mortality among patients on selexipag than those undergoing other PAH treatments. Patients with pulmonary arterial hypertension (PAH) undergoing selexipag ...

Selexipag is an oral prostacyclin agonist that shows promise in treating both adult and pediatric patients with PAH. Selexipag, an oral prostacyclin agonist, demonstrated considerable effectiveness ...

Alembic Pharmaceuticals Ltd announced on Monday that it has received tentative approval from the US Food & Drug Administration (USFDA) for its generic version of Selexipag injection, used to treat ...

Upon final approval of this ANDA by USFDA, Alembic may be eligible for 180 days of generic marketing exclusivity in the U.S. (Image Credits: Pixabay) Alembic Pharmaceuticals Limited on Monday ...

New Delhi: Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) ...

Alembic Pharmaceuticals Ltd announced on Monday that it has obtained tentative approval from the US Food & Drug Administration (USFDA) for its generic version of Selexipag injection, a drug used to ...